Johnson & Johnson navigates the loss of exclusivity for its blockbuster immunology drug, Stelara.
Stelara sales declined by $913 million in the second quarter of 2026. Newer growth products generated $2.43 billion in revenue. This revenue more than offset the Stelara decline.
Immunology treatment Tremfya and oncology drugs Darzalex and Carvykti drove this performance.
J&J's Innovative Medicine division grew despite the Stelara headwind.
The company raised its full-year 2026 sales guidance. It projects revenues to approach or exceed $101 billion.
Analysts note weaker growth in the MedTech division.